Gemcitabine remains a mainstay in cancer treatment, but scientists are exploring how it can work alongside cutting-edge therapies. While some drug combinations have failed to improve outcomes, other ...

In this study, researchers aimed to examine survival outcomes with elraglusib plus chemotherapy compared to chemotherapy alone in untreated mPDAC.

Credit: Getty Images Investigators report their early clinical experience using intravesical sequential gemcitabine-docetaxel as first-line therapy for high-risk nonmuscle-invasive bladder cancer.

Liposomal gemcitabine in combination with pembrolizumab shows promise in the treatment of advanced solid tumors, according to a study presented at the recent American Society of Clinical Oncology ...

Gloved hand holding infusion line. Source: Getty Images Investigators report significantly improved cancer-specific and overall survival. WASHINGTON, DC—Sequential intravesical gemcitabine-docetaxel ...

IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX -- IDE ...

Please provide your email address to receive an email when new articles are posted on . Antibiotic receipt in the month before or after gemcitabine treatment improved survival in metastatic pancreatic ...

Please provide your email address to receive an email when new articles are posted on . Intra-arterial administration of gemcitabine conferred a median PFS benefit of 8 months when compared with ...

Development of a gene expression-based test for the detection of endometrial cancer in uterine aspirates. Background: Cervical cancer is one of the leading causes of death among women in developing ...

Accepted Abstract is a Sub-Study in RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial and Explores the TAMP™ Therapy Platform’s Potential to Increase Local Drug Potency and Reduce Systemic ...